Trial Profile

A phase III study of PfSPZ Vaccine to evaluate safety, protection and operational efficiency in support of licensure

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 17 Apr 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Apr 2019 According to a Sanaria media release, and the Government of Equatorial Guinea, US Energy Companies, and Sanaria signed an agreement to support clinical development of Sanaria PfSPZ Vaccine as a tool for malaria elimination, including the Phase 3 clinical program starting in 2020.
10 Apr 2019 According to a Sanaria media release, a phase III clinical program is expected to initiate in early 2020.
10 Apr 2019 According to a Sanaria media release, this trial will provide data to support submission to US and European regulatory agencies for licensure of PfSPZ Vaccine.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com